IMCD N.V.
IMCD reports EBITA of EUR 275 million in the first half of 2025
IMCD reports EBITA of EUR 275 million in the first half of 2025
Rotterdam, The Netherlands (30 July 2025) - IMCD N.V. ("IMCD" or "Company"), a global leading partner for the distribution and formulation of speciality chemicals and ingredients, today announces its first half 2025 results.
HIGHLIGHTS
• Gross profit up by 5% to EUR 634 million (+7% on a constant currency basis)
• Operating EBITA up by +2% to EUR 275 million (+4% on a constant currency basis)
• Free cash flow of EUR 173 million (first half 2024: EUR 221 million)
• Cash earnings per share at EUR 2.94 (first half 2024: EUR 3.23)
• Expanding our footprint across key markets through six completed acquisitions year to date
Marcus Jordan, CEO: "In the first half of 2025 we delivered forex adjusted gross profit growth of 7% and EBITA growth of 4%. We completed six acquisitions across our three regions to further strengthen our capabilities in a range of core market segments. Under challenging and unpredictable macro-economic market conditions, I am assured by the resilience of our asset-light business model and thankful to our teams for their continued growth focus. While these challenging conditions may persist, we are well positioned for the future through our leading speciality focused portfolio, geographic and market diversity combined with advanced digital and supply chain capabilities."
Attachment
Documents
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Financière de Tubize SA2.8.2025 08:00:00 CEST | Press release
Financière de Tubize - 2025 half-year financial report
DBV Technologies S.A.1.8.2025 22:05:00 CEST | Press release
Information regarding the total number of voting rights and total number of shares of the Company as of July 31, 2025
Mandalay Resources Corporation1.8.2025 21:12:01 CEST | Press release
Mandalay Obtains Final Order Approving Arrangement with Alkane
F. Hoffmann-La Roche Ltd1.8.2025 20:00:00 CEST | Press release
Roche’s Susvimo maintains vision over five years with two refills per year in people with neovascular age-related macular degeneration (nAMD)
KBC Groep1.8.2025 18:10:00 CEST | Press release
KBC Group: KBC remains well-capitalised under 2025 EU-wide EBA stress test
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom